Oncology News

ESMO oncology news ensures that you're always kept up to date with the latest developments that affect you and your daily practice. Make sure you check these pages frequently, or sign up to our newsletter.

Filter

23 Dec 2016 EMA Adopts a New Indication for 5-Aminolevulinic Acid Melanoma and other skin tumours - Anticancer agents & Biologic therapy
21 Dec 2016 EMA Recommends Granting a Marketing Authorisation for the Hybrid Medicine Chlormethine Haematologic malignancies - Anticancer agents & Biologic therapy
21 Dec 2016 FDA Grants Accelerated Approval to Rucaparib for Previously Treated, BRCA Mutated Advanced Ovarian Cancer Personalised medicine - Gynaecologic malignancies - Anticancer agents & Biologic therapy
20 Dec 2016 EMA Recommends Granting a Marketing Authorisation for Biosimilar Rituximab Haematologic malignancies - Anticancer agents & Biologic therapy
19 Dec 2016 EMA Recommends to Extend Indications for Pembrolizumab Lung and other thoracic tumours - Cancer Immunology and Immunotherapy
18 Dec 2016 ESMO Asia 2016 Press Release: Ribociclib Improves Progression-free Survival in Asian Women with Advanced Breast Cancer Breast cancer
18 Dec 2016 ESMO Asia 2016 Press Release: Anxiety and Depression a Major Issue for Cancer Survivors
18 Dec 2016 ESMO Asia 2016 Press Release: Cancer Costs Leaving Patients in Debt Bioethics, legal and economic issues
18 Dec 2016 ESMO Asia 2016 Press Release: Immunotherapy with Pembrolizumab Deemed Cost-Effective for Advanced Melanoma Patients in Hong Kong Melanoma and other skin tumours - Cancer Immunology and Immunotherapy
18 Dec 2016 ESMO Asia 2016 Press Release: Routine Blood Test Predicts How Long Cancer Patients Will Survive Palliative and supportive care
18 Dec 2016 ESMO Asia 2016 Press Release: Depressed Patients Are Less Responsive to Chemotherapy Anticancer agents & Biologic therapy
17 Dec 2016 ESMO Asia 2016 Press Release: First Data on Rare Sarcomas in Asian Patients Presented at ESMO Asia in Singapore Sarcomas
16 Dec 2016 EMA Recommends Granting a Conditional Marketing Authorisation for Alectinib for the Treatment of ALK-Positive Advanced NSCLC Lung and other thoracic tumours - Anticancer agents & Biologic therapy
16 Dec 2016 ESMO Asia 2016 Press Release: Asian Head and Neck Cancer Patients Live Longer with Immunotherapy than Mixed Race Group Head and neck cancers